Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty

In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP). Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids. Gonadotropin-releasing hormone anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Katherine A, Eugster, Erica A
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769233/
https://www.ncbi.nlm.nih.gov/pubmed/19920916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769233/
https://www.ncbi.nlm.nih.gov/pubmed/19920916

Ejemplares similares